CDXC — Chromadex Income Statement
0.000.00%
Last trade - 00:00
- $269.56m
- $241.85m
- $83.57m
- 91
- 17
- 76
- 64
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46.3 | 59.3 | 67.4 | 72 | 83.6 |
Cost of Revenue | |||||
Gross Profit | 25.8 | 35.3 | 41.5 | 42.8 | 50.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 77.6 | 79.1 | 94.5 | 90.7 | 89.2 |
Operating Profit | -31.3 | -19.9 | -27.1 | -18.6 | -5.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -32.1 | -19.9 | -27.1 | -16.5 | -4.94 |
Net Income After Taxes | -32.1 | -19.9 | -27.1 | -16.5 | -4.94 |
Net Income Before Extraordinary Items | |||||
Net Income | -32.1 | -19.9 | -27.1 | -16.5 | -4.94 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -32.1 | -19.9 | -27.1 | -16.5 | -4.94 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.563 | -0.326 | -0.404 | -0.237 | -0.066 |